Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Famprofazone SCHEMBL893454 | 1.00 | LMNA (1.00) | LMNANR1I2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4327273 | 0.86 | LMNA (0.75) | LMNANR1I2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11287540 | 0.75 | LMNA (0.65) | LMNANR1I2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3526669 | 0.75 | LMNA (0.65) | LMNANR1I2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3527994 | 0.72 | LMNA (0.60) | LMNANR1I2CYP3A4CYP2D6CYP2C9 | |
| Propyphenazone SCHEMBL27899010 | 0.71 | LMNA (0.70) | LMNANR1I2CYP3A4CYP2D6CYP2C9 | |
| Propyphenazone SCHEMBL23393 | 0.70 | LMNA (1.00) | LMNACYP2D6PTGS2ADORA3POLB | |
| Benzphetamine SCHEMBL678807 | 0.69 | ADRA2B (1.00) | LMNANR1I2CYP3A4CYP2D6CYP2C9 | |
| Benzphetamine SCHEMBL49120 | 0.69 | ADRA2B (1.00) | LMNANR1I2CYP3A4CYP2D6CYP2C9 | |
| Benzphetamine SCHEMBL19285634 | 0.69 | ADRA2B (1.00) | LMNANR1I2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ACERAGEN INC (US) | 2026-01-01 | — | — | US | claimed |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-10-12 | — | — | US | claimed |
| EP-4192579-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-06-14 | — | — | EP | claimed |
| US-20220387466-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND/OR TREATMENT OF DYSBIOSIS AND ANTIBACTERIAL ANTIDOTES FOR MICROBIOME-PROTECTION | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2022-12-08 | — | — | US | claimed |
| EP-4076411-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND/OR TREATMENT OF DYSBIOSIS AND ANTIBACTERIAL ANTIDOTES FOR MICROBIOME-PROTECTION | European Molecular Biology Laboratory (DE) | 2022-10-26 | — | — | EP | claimed |
| US-20220088158-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ROIVANT SCIENCES, INC. | 2022-03-24 | — | — | US | claimed |
| WO-2022032077-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | REDUX THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| WO-2021122809-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND/OR TREATMENT OF DYSBIOSIS AND ANTIBACTERIAL ANTIDOTES FOR MICROBIOME-PROTECTION | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2021-06-24 | — | — | WO | claimed |
| EP-3838269-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND/OR TREATMENT OF DYSBIOSIS AND ANTIBACTERIAL ANTIDOTES FOR MICROBIOME-PROTECTION | European Molecular Biology Laboratory (DE) | 2021-06-23 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-2188630-A2 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2010-05-26 | — | — | EP | claimed |
| WO-2009045443-A2 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2009-04-09 | — | — | WO | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-6929805-B2 | For oral administration comprising an analgesic with rapid onset of action and at least one systemically acting analgesic with sustained action, such as a combination of benzocaine and acetylsalicylic acid (ASA) | BAYER AKTIENGESELLSCHAFT (DE) | 2005-08-16 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-4181719-A | Analgesic N-acetyl-para-aminophenyl N'-acetylaminothioalkanoates | STERLING DRUG INC. (US) | 1980-01-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | LIPC, CPT1A, CETP | LMNA 2305/4885NR1I2 1320/4885CYP3A4 1150/4885 |
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ASAH2, ASAH1, GBA2 | LMNA 1898/4885NR1I2 1617/4885CYP3A4 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.